Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

Completed · Phase 1 · Has a placebo group

Conditions studied: Safety, Phosphate Binding Capacity

In brief

The purpose of this trial is to study safety, tolerability, and phosphate binding capacity of Renazorb (SPI-014) in healthy volunteers before conducting trials in patients with renal failure. Renal excretion of phosphate is expected to decrease and fecal excretion of phosphate is expected to increase after treatment.

Key facts

Study ID

NCT01560884

Run by

Spectrum Pharmaceuticals, Inc

People needed

32

Starts

2012-04-01

Expected to finish

2012-09-01

Last updated by the study team

2013-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female volunteers ≥ 18 years of age without history of significant medical disease will be enrolled.

Where it is running

• PAREXEL International - Baltimore Early Phase Clinical Unit — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.